Case Scenario 1: Breast

Similar documents
Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Boot Camp Case Scenarios

SEER Summary Stage Still Here!

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Prostate Case Scenario 1

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Definition of Synoptic Reporting

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Radiology Pathology Conference

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Melanoma Case Scenario 1

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

3. This data item records the grade of a solid primary tumor that had been resected following neoadjuvant therapy. a. Grade Post Therapy

Melanoma Case Scenario 1

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Melanoma Quality Reporting

OBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.

Kidney Case 1 SURGICAL PATHOLOGY REPORT

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

GUIDELINES ON PROSTATE CANCER

Charles Mulligan, MD, FACS, FCCP 26 March 2015

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

A215- Urinary bladder cancer tissues

STAGE CATEGORY DEFINITIONS

3D Conformal Radiation Therapy for Mucinous Carcinoma of the Breast

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Case Scenario 1: Thyroid

Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.

Breast Cancer. Saima Saeed MD

Robotic-assisted right upper lobectomy

Pathology Report Patient Companion Guide

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

Mediastinal Staging. Samer Kanaan, M.D.

11/21/13 CEA: 1.7 WNL

Metachronic solitary breast metastasis from renal cell carcinoma: case report

Breast Cancer Diagnosis, Treatment and Follow-up

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

Radiology Pathology Conference

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

Update on Reporting Prostate Cancer Pathology

ACRIN 6666 Therapeutic Surgery Form

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Major Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the

Quiz. b. 4 High grade c. 9 Unknown

Parenchyma-sparing lung resections are a potential therapeutic

Seventh Edition Staging 2017 Breast

Chapter 2 Staging of Breast Cancer

3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Breast Cancer. Pathologic Staging Updates Breast Cancer

Handout for Dr Allison s Lectures on Grossing Breast Specimens:

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

Prostate Cancer Local or distant recurrence?

Case study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research

Pathology: Grade 1 infiltrating ductal carcinoma with associated DCIS, Lymphvascular invasion present. ER+, PR+. Her 2/ IHC 1+, negative

Guidelines for Assigning Summary Stage 2000

Educational Objectives. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach.

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Collaborative Staging

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

57th Annual HSCP Spring Symposium 4/16/2016

Adam J. Hansen, MD UHC Thoracic Surgery

Pancreas Case Scenario #1

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast

Staging for Residents, Nurses, and Multidisciplinary Health Care Team

3D Conformal Radiation Therapy for Invasive Ductal Carcinoma of the Left Breast

Robotic-assisted right inferior lobectomy

PET/CT Frequently Asked Questions

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Table of contents. Page 2 of 40

Radiology-Pathology Conference

2016 AJCC TNM Practice Cases (You Will Need an AJCC Staging Manual)

Pathology Reports in Underwriting

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

Cancer Program Report 2014

Image guided core biopsies:

Prostate Overview Quiz

National Center of Oncology - Yerevan, Armenia

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

NAME/ AGE/57 SEX/Female AREA/Australia Visit 1: 5/8/2011. Right Breast Cancer Infiltrating Ductal Carcinoma, no specific type, Grade 1 to 2.

Transcription:

Case Scenario 1: Breast A 63 year old white female presents with a large mass in her left breast. 4/15/13 Mammogram/US: 1. Left breast mammographic and sonographic at 3:00 measuring 7.1 cm highly suggestive of malignancy. 2. Questionable adjacent 3:00 satellite nodule versus cyst was noted. 3. Left breast 2 adjacent 4:00 probable complicated cysts. A cyst aspiration was recommended to exclude satellite nodules. 4. Abnormal left axillary lymph nodes. 4/19/13 Final Diagnosis Breast Biopsy: Left breast bx: Invasive ductal ca, grade 3 Left axillary lymph node biopsy: neg for malignancy Estrogen Receptor: POSITIVE. Progesterone Receptor: NEGATIVE. HER2 IHC Result: EQUIVOCAL (SCORE = 2 +). HER2 Gene Amplification by FISH: POSITIVE (AMPLIFIED). 4/25/13-Neoadjuvant Adriamycin, cyclophosphamide, taxol followed by Herceptin 8/20/13 Left breast wire-directed partial mastectomy, SLN biopsy FINAL DIAGNOSIS A) LYMPH NODE, LEFT AXILLA - COLD, EXCISIONAL BIOPSY: - NO TUMOR SEEN IN 1 OF 1 LYMPH NODE. B) LYMPH NODE, LEFT AXILLA - SENTINEL NODE, BIOPSY: - NO TUMOR SEEN IN 1 OF 1 LYMPH NODE BY HISTOLOGY OR ANTIKERATIN AE1/AE3 IMMUNOHISTOCHEMISTRY. C) LEFT BREAST, PARTIAL MASTECTOMY: HISTOLOGIC TUMOR TYPE: INVASIVE DUCTAL CARCINOMA. SIZE OF INVASIVE TUMOR: 1.2 x 1.1 x 1.0 CM. COMPOSITE HISTOLOGIC GRADE: III (POORLY DIFFERENTIATED). Tubule formation score: 3 Nuclear pleomorphism score: 3 Mitotic count score: 2 Total Nottingham score: 8 DUCTAL CARCINOMA IN-SITU: HIGH-GRADE DCIS ASSOCIATED WITH TUMOR MASS.

LYMPH-VASCULAR INVASION: NONE IDENTIFIED. MARGINS: ALL MARGINS FREE FROM INVASIVE CARCINOMA AND DCIS; CLOSEST MARGIN IS THE INFEROPOSTERIOR MARGIN WHICH IS 0.4 CM. FROM TUMOR. D) LEFT BREAST 6:00 MARGIN, EXCISION: Diagnostic Comments: The partial mastectomy specimen shows invasive ductal carcinoma; there is ductal carcinoma in-situ associated with the main tumor mass. The invasive carcinoma and DCIS are free from specimen margins, the closest margin being the inferoposterior margin which is 0.4 cm. from the tumor. In the separately submitted "new 6:00 margin" specimen, there are two stray fragments of cauterized tissue in one of the tissue blocks (one of which contains DCIS); however, these two stray fragments do not appear to be part of the new margin specimen. All margins of the partial mastectomy specimen and the "new 6:00 margin" specimen appear free from malignancy. 9/7/13 Medical Oncology: Completion of neoadjuvant regimen: Adriamycin, cyclophosphamide, taxol followed by Herceptin 10/19/13-1/12/14 Radiation Oncology: The left breast received 50.4 Gy in 28 sessions utilizing 6 and 18 MV photons, tangential portals, and a field-in-field technique. The tumor bed was boosted an additional 10 Gy in 5 treatments for a total of 60.4 Gy in 33 treatments. The tumor bed was treated utilizing 20 MeV electrons and an enface treatment portal. 1/9/14 Medical Oncology: Anastrozole ct3 cn0 cm0 Clinical Stage IIB ypt1c ypn0 (i-) pm ypathologic Stage IA Summary Stage 1 Localized

Case Scenario 2: Lung A 54 year white male presents with a recent abnormal CT of the chest. The patient has a history of melanoma, kidney, and prostate cancers. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded. 10/26/13 CT Chest: 2.8 cm speculated soft tissue mass inferior lingular segment consistent with malignancy. This could represent either a primary such as bronchogenic carcinoma or a metastasis. Indeterminate non-calcified sub centimeter soft tissue nodules of unknown malignant potential (one within left upper lobe and one within the right upper lobe). 11/12/13 PET/CT: A 2.9 cm diameter spiculated mass in the lingula demonstrates abnormally increased FDG accumulation (max SUV = 11.9). This is consistent with malignancy. No additional sites of abnormally increased FDG accumulation are visualized elsewhere. Specifically, no abnormal FDG accumulation to correspond to the sub centimeter nodules visualized on the outside CT study in the upper lobes bilaterally. Although the absence of visible FDG accumulation favors a benign etiology, the small size of the nodules reduces the sensitivity of FDG-PET imaging for detecting malignancy. 12/5/13 Operative Report: Left thoracoscopic wedge resection and left upper lobectomy: With the patient under adequate general tracheal anesthesia, bronchoscopy was performed. No endobronchial lesions identified. With the double-lumen endotracheal tube positioned, in the full lateral position with the left side up, patient prepped and draped. Three access ports were utilized, through which a 10 mm rigid thoracoscope was introduced. There were no significant adhesions. The lesion was identified in the lingular area in the upper lobe. A generous wedge resection was performed using the endoscopic stapler. The specimen was removed in a sterile bag and sent for frozen section evaluation, which proved to be an adenocarcinoma. It did not appear to be metastatic. Therefore, the upper lobe was resected in standard fashion. The heavy black load was used to cross the bronchus, purple loads across the other vascular structures. The specimen was removed. The bronchial stump was checked and was air tight. The area was irrigated out. Mediastinal nodes were sampled. Path: Final Diagnosis: A) LUNG, LEFT UPPER LOBE, WEDGE BIOPSY: -HISTOLOGIC TUMOR TYPE: INVASIVE MODERATE DIFFERENTIATED ADENOCARCINOMA. -HISTOLOGIC TUMOR GRADE: GRADE 2 (OF 4). -TUMOR FOCALITY: UNIFOCAL. -TUMOR SIZE: 2.9 X 2.5 X 2.3 CM. -VISCERAL PLEURA INVOLVEMENT: PRESENT (PL1 HIGHLIGHTED WITH VVG STAIN). -VASCULAR INVASION: NOT IDENTIFIED. -MARGINS: SURGICAL MARGIN IS NEGATIVE FOR TUMOR. -ADDITIONAL PATHOLOGIC FINDINGS: EMPHYSEMATOUS CHANGES AND BRONCHIECTASIS.

B) LYMPH NODE (1), MEDIASTINAL, EXCISION: C) LUNG, LEFT UPPER LOBE, LOBECTOMY: - NO RESIDUAL TUMOR IDENTIFIED. - THE SURGICAL MARGINS ARE NEGATIVE. - A SINGLE BENIGN LYMPH NODE IS IDENTIFIED. D) LYMPH NODE (1), AP WINDOW, EXCISION: E) LYMPH NODE (1), INFERIOR PULMONARY LIGAMENT, EXCISION: - HYALINIZED GRANULOMATOUS INFLAMMATION. ct1b cn0 cm0 Clinical Stage IA pt2a pn0 pm Pathologic Stage IB Summary Stage 2 Regional by Direct Extension

Case Scenario 3: Prostate 2/4/13 HISTORY: 68-year-old white male with elevated PSA, 3.99, on routine screening in January. DRE: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule involving less than half of the left lateral lobe of the prostate gland. The prostate is otherwise smooth and firm. 3/8/13 TRUS: The prostate gland had a normal sonographic appearance throughout. The height, width and length method were used to estimate the volume, which was 26.7 cm 3. Using ultrasound guidance lidocaine 1%, 5 ml was injected posterolaterally near each seminal vesical. After a few minutes, systematic biopsies were performed. Using ultrasound guidance, two needle core biopsies were obtained from the lateral edge, and three were obtained medially on each side of the gland. One of the medial biopsies on each side traversed the apex of the prostate. 3/8/13 PROSTATE BIOPSY: Prostate, left, needle biopsy: Adenocarcinoma, Gleason score 3+4=7, involving 5 of 5 cores and 90% of specimen. Perineural invasion is present. No lymphovascular invasion identified. No extraprostatic extension identified. No seminal vesicle tissue present for evaluation. Prostate, right, needle biopsy: Adenocarcinoma, Gleason score 3+4=7, involving 4 of 5 cores and 30% of specimen. No perineural or lymphovascular invasion identified. No extraprostatic extension identified. No seminal vesicle tissue present for evaluation. 4/19/13 BONE SCAN: No scintigraphic findings to suggest skeletal metastases. 4/20/13 CT A/P: There are multiple cystic like lesion within the liver with one indeterminate lesion in the inferior aspect of the left lobe of the liver. If there is a high clinical suspicion for metastatic disease, recommend further evaluation with MRI of the abdomen. 5/27/13 PROSTATE GLAND, ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY AND BILATERAL PELVIC LYMPHADENECTOMY: A. Prostate Histologic tumor type: Adenocarcinoma Histologic tumor grade: Gleason score 3+4=7 Tumor quantitation: Tumor involves right and left lobes with predominant involvement of the left lobe. Tumor involves approximately 60% of the left lobe and approximately 30% of the right lobe. Extraprostatic tumor extension: Not identified. Perineural invasion: Extensive perineural invasion is present. Lymph vascular invasion: Not identified. Margins: Apical, bladder neck and peripheral soft tissue inked margins are free of tumor. Seminal vesicle muscle wall invasion: No evidence of malignancy right and left seminal vesicles. Right pelvic lymph nodes (part C): No evidence of malignancy, 6 lymph nodes.

Left pelvic lymph nodes (part D): No evidence of malignancy, 10 lymph nodes. B. Left posterior lateral margin: No evidence of malignancy. C. Lymph nodes, right pelvic lymph node dissection: No evidence of malignancy, 6 lymph nodes. D. Lymph nodes, left pelvic lymph node dissection: No evidence of malignancy, 10 lymph nodes. ct2a cn0 cm0 Clinical Stage IIA pt2c pn0 pm Pathologic Stage IIB Summary Stage 1 Localized